Apertura has entered a CRADA with various NIH institutes for a gene therapy to treat Niemann-Pick Disease Type C1 (NPC1).
Teva Pharmaceuticals International and Polpharma Biologics have signed a global licensing agreement for a proposed biosimilar to Ocrevus to treat multiple sclerosis.
AstraZeneca and Sino Biopharmaceutical's subsidiary CTTQ have signed an exclusive licence agreement for TQC3721.
Over 156,000 adults in Europe are hospitalised each year due to RSV, a virus that can cause severe lung issues.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results